) was a big mover last session, as the company saw its shares rise
by nearly 64% on the day on the back of positive study data for its
obesity treatment Maestro system. The move came on solid volume too
with far more shares changing hands than in a normal session. This
reverses the recent trend of the company, as the stock is now
trading above the near-flat price range of $1.27 to $1.40 in the
past one-month time frame.
The company has seen one negative estimate revision in the past 30
days and its Zacks Consensus Estimate moved a notch lower,
suggesting there may be trouble down the road. So make sure to keep
an eye on this stock going forward to see if this recent move
higher can last.
EnteroMedics currently has a Zacks Rank #4 (Sell) while its
Some better-ranked stocks in the medical products sector include
Hill-Rom Holdings, Inc.
). While NuVasive and Hill-Rom Holdings hold a Zacks Rank #1
(Strong Buy), Exactech carries a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download
7 Best Stocks for the Next 30 Days
Click to get this free report >>
ENTEROMEDICS IN (ETRM): Free Stock Analysis
EXACTECH INC (EXAC): Free Stock Analysis Report
HILL-ROM HLDGS (HRC): Free Stock Analysis
NUVASIVE INC (NUVA): Free Stock Analysis Report
To read this article on Zacks.com click here.